RGEN Stock — Repligen Corporation

Repligen Corporation (RGEN)

Updated October 16, 2026.

RGEN is a Stock. Total return is 1450.7% over the past 40.5 years.

Repligen Corporation is a life sciences company that develops bioprocessing technologies and systems for biopharmaceutical manufacturing, including chromatography resins, filtration systems, process analytics tools, and cell culture products sold to drug manufacturers and contract manufacturing organizations globally. The company does not currently distribute dividends. Repligen is oriented toward growth in the biopharmaceutical processing market rather than income generation.

RGEN performance

Price and return data through 2026-10-16.

Total return is 1450.7% over the past 40.5 years. Over the past year its total return — price change plus distributions reinvested — is 13.5%. Its deepest 1-year drawdown was 40.3%.

RGEN key facts

Asset type

Stock

Asset class

Equity

Inception date

04/29/1986

Distribution frequency

None

Last close

$175.42 (as of 2026-10-16)

Market cap

$11,137,479,828

Average volume

1213299.0

Beta

1.077

Payout ratio

0.0%

P/E ratio

240.3

Forward P/E

67.1141

EPS

$0.73

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RGEN risks and drawbacks

The deepest 1-year drawdown on record here is 40.3%.

Who may consider RGEN — and who may not

It is a weaker fit for investors who need monthly cash flow (RGEN does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on RGEN

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions